无并发症B型主动脉夹层预防性胸主动脉腔内修复术的最佳时机:一项网状Meta分析
该网状Meta分析比较了单纯优化药物治疗与不同慢性期阶段预防性胸主动脉腔内修复术(TEVAR)治疗无并发症B型主动脉夹层的结局。结果显示亚急性期TEVAR的短期死亡率和长期全因死亡率较低,急性期TEVAR卒中发生率较高,优化药物治疗的长期死亡率较高。作者认为亚急性期(症状发作后14-90天)可能是预防性TEVAR的最佳时机。
要点
- 亚急性期TEVAR短期死亡率低于急性期(HR 0.60,95%CI 0.38-0.94,p=0.027)。
- 急性期TEVAR卒中发生率高于亚急性期、慢性期和优化药物治疗。
- 优化药物治疗长期全因死亡率高于亚急性期TEVAR(HR 1.67,95%CI 1.25-2.33,p<0.001)。
核心结论
- 预防性TEVAR相比优化药物治疗可能降低全因死亡率和主动脉相关死亡率。
- 综合短期死亡率、围术期卒中率和长期死亡率,研究结果支持在亚急性期进行预防性TEVAR。
研究设计与样本
- 网状Meta分析,检索MEDLINE和EMBASE截至2023年11月。
- 系统评价纳入17项研究(2项随机对照试验、3项倾向性评分匹配、2项逆概率加权)。
主要发现
- 亚急性期干预短期死亡率低于急性期(HR 0.60,95%CI 0.38-0.94,p=0.027)。
- 急性期TEVAR卒中发生率高于亚急性期(HR 2.63,95%CI 1.36-5.09,p=0.042)、慢性期(HR 2.5,95%CI 1.03-6.2,p=0.043)和优化药物治疗(HR 1.57,95%CI 1.12-2.18,p=0.008)。
- 急性期TEVAR长期全因死亡率高于亚急性期干预(HR 1.34,95%CI 1.03-1.74,p=0.03)。
- 优化药物治疗长期全因死亡率高于亚急性期TEVAR(HR 1.67,95%CI 1.25-2.33,p<0.001),长期主动脉相关死亡率高于急性期(HR 2.08,95%CI 1.31-3.31,p=0.002)和亚急性期(HR 2.6,95%CI 1.62-4.18,p<0.01)干预。
- 主动脉再干预率无显著差异;主动脉破裂和截瘫无显著差异。
关键数值与推荐
- 亚急性期定义为症状发作后14-90天。
临床怎么用
- 作者认为,综合短期死亡率、围术期卒中率和长期死亡率,研究结果支持在亚急性期进行预防性TEVAR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This network meta-analysis compares outcomes of optimal medical therapy (OMT) and pre-emptive thoracic endovascular aortic repair (TEVAR) for uncomplicated type B aortic dissection at different phases of chronicity. METHODS: MEDLINE and EMBASE were searched through November 2023. Pooled short-term outcomes (short-term mortality, perioperative complications) and long-term outcomes (all-cause mortality, aortic-related mortality, aortic re-intervention rates) were calculated. RESULTS: Systematic review identified 17 studies (2 randomized controlled trials, 3 propensity score matching, and 2 inverse probability weighting). Subacute-phase intervention had lower short-term mortality than the acute-phase (hazard ratio [HR] [95% confidence interval [CI]]=0.60 [0.38-0.94], p=0.027). No significant differences were observed in aortic rupture and paraplegia. Acute-phase TEVAR had a higher stroke incidence than subacute-phase intervention (HR [95% CI]=2.63 [1.36-5.09], p=0.042), chronic (HR [95% CI]=2.5 [1.03-6.2], p=0.043), and OMT (HR [95% CI]=1.57 [1.12-2.18], p=0.008). Acute-phase TEVAR had higher long-term all-cause mortality than subacute-phase intervention (HR [95% CI]=1.34 [1.03-1.74], p=0.03). Optimal medical therapy had elevated long-term all-cause mortality compared with subacute-phase TEVAR (HR [95% CI]=1.67 [1.25-2.33], p<0.001) and increased long-term aortic-related mortality vs acute-phase (HR [95% CI]=2.08 [1.31-3.31], p=0.002) and subacute-phase (HR [95% CI]=2.6 [1.62-4.18], p<0.01) interventions. No significant differences were observed in aortic re-intervention rates. CONCLUSIONS: Pre-emptive TEVAR may offer lower all-cause mortality and aortic-related mortality than OMT. Considering lower short-term mortality, perioperative stroke rate, and long-term mortality, our findings support pre-emptive TEVAR during the subacute phase.Clinical ImpactThe optimal timing of pre-emptive thoracic endovascular aortic repair (TEVAR) for uncomplicated type B aortic dissection remains uncertain. This network meta-analysis suggests that the subacute phase (14-90 days from symptom onset) emerges as the optimal timing for pre-emptive TEVAR. This window is associated with lower rates of short-term complications and higher long-term survival rates compared with alternative strategies.
引用
- Naito N, Takagi H. Optimal Timing of Pre-emptive Thoracic Endovascular Aortic Repair in Uncomplicated Type B Aortic Dissection: A Network Meta-Analysis. J Endovasc Ther. 2024. PMID: 38590280. doi:10.1177/15266028241245282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。